Legend Biotech Corporation (LEGN) has released an update.
Legend Biotech Corporation has reported promising first quarter 2024 financial results, with significant growth in CARVYKTI® sales and strategic expansions, including a new agreement with Novartis for increased manufacturing capacity. The company’s advancements have led to label expansions in multiple regions, positioning CARVYKTI® to reach more patients with multiple myeloma. With a strong cash reserve, Legend Biotech is poised for continued growth and anticipates turning an operating profit by 2026.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
